- Home
- TTGT vs PCRX Comparison
TTGT vs PCRX Comparison
Compare TTGT & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TTGT
- PCRX
- Stock Information
- Founded
- TTGT 1999
- PCRX 2006
- Country
- TTGT United States
- PCRX United States
- Employees
- TTGT N/A
- PCRX N/A
- Industry
- TTGT Telecommunications Equipment
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- TTGT Telecommunications
- PCRX Health Care
- Exchange
- TTGT Nasdaq
- PCRX Nasdaq
- Market Cap
- TTGT 961.8M
- PCRX 1.1B
- IPO Year
- TTGT 2007
- PCRX 2011
- Fundamental
- Price
- TTGT $12.76
- PCRX $24.07
- Analyst Decision
- TTGT Buy
- PCRX Buy
- Analyst Count
- TTGT 7
- PCRX 9
- Target Price
- TTGT $28.00
- PCRX $30.67
- AVG Volume (30 Days)
- TTGT 242.6K
- PCRX 839.2K
- Earning Date
- TTGT 03-31-2025
- PCRX 05-06-2025
- Dividend Yield
- TTGT N/A
- PCRX N/A
- EPS Growth
- TTGT N/A
- PCRX N/A
- EPS
- TTGT N/A
- PCRX N/A
- Revenue
- TTGT $260,750,999.00
- PCRX $700,966,000.00
- Revenue This Year
- TTGT $26.95
- PCRX $9.37
- Revenue Next Year
- TTGT N/A
- PCRX $11.30
- P/E Ratio
- TTGT N/A
- PCRX N/A
- Revenue Growth
- TTGT 31.84
- PCRX 3.85
- 52 Week Low
- TTGT $12.66
- PCRX $11.16
- 52 Week High
- TTGT $35.10
- PCRX $31.67
- Technical
- Relative Strength Index (RSI)
- TTGT 36.60
- PCRX 48.76
- Support Level
- TTGT $14.48
- PCRX $23.93
- Resistance Level
- TTGT $15.39
- PCRX $25.88
- Average True Range (ATR)
- TTGT 0.98
- PCRX 0.92
- MACD
- TTGT 0.07
- PCRX 0.12
- Stochastic Oscillator
- TTGT 4.62
- PCRX 52.99
About TTGT TechTarget Inc.
TechTarget Inc is engaged in the business-to-business (B2B) accelerator, informing and influencing technology buyers and sellers. Through its B2B first-party data and an end-to-end portfolio of data-driven solutions, it services the full B2B product lifecycle for customers from, messaging, and content development to in-market activation via brand, demand generation, purchase intent data, and sales enablement from R&D to ROI.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.